Skip to Content
Merck
  • AAV8-mediated in vivo overexpression of miR-155 enhances the protective capacity of genetically attenuated malarial parasites.

AAV8-mediated in vivo overexpression of miR-155 enhances the protective capacity of genetically attenuated malarial parasites.

Molecular therapy : the journal of the American Society of Gene Therapy (2014-09-06)
Franziska Hentzschel, Christiane Hammerschmidt-Kamper, Kathleen Börner, Kirsten Heiss, Bettina Knapp, Julia M Sattler, Lars Kaderali, Mirco Castoldi, Julia G Bindman, Yann Malato, Holger Willenbring, Ann-Kristin Mueller, Dirk Grimm
ABSTRACT

Malaria, caused by protozoan Plasmodium parasites, remains a prevalent infectious human disease due to the lack of an efficient and safe vaccine. This is directly related to the persisting gaps in our understanding of the parasite's interactions with the infected host, especially during the clinically silent yet essential liver stage of Plasmodium development. Previously, we and others showed that genetically attenuated parasites (GAP) that arrest in the liver induce sterile immunity, but only upon multiple administrations. Here, we comprehensively studied hepatic gene and miRNA expression in GAP-injected mice, and found both a broad activation of IFNγ-associated pathways and a significant increase of murine microRNA-155 (miR-155), that was especially pronounced in non-parenchymal cells including liver-resident macrophages (Kupffer cells). Remarkably, ectopic upregulation of this miRNA in the liver of mice using robust hepatotropic adeno-associated virus 8 (AAV8) vectors enhanced GAP's protective capacity substantially. In turn, this AAV8-mediated miR-155 expression permitted a reduction of GAP injections needed to achieve complete protection against infectious parasite challenge from previously three to only one. Our study highlights a crucial role of mammalian miRNAs in Plasmodium liver infection in vivo and concurrently implies their great potential as future immune-augmenting agents in improved vaccination regimes against malaria and other diseases.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Pluripotin, ≥98% (HPLC)
Sigma-Aldrich
D-Luciferin, synthetic, BioXtra, ≥99% (HPLC)
Sigma-Aldrich
Trypan Blue, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
D-Luciferin, synthetic
Sigma-Aldrich
Trypan Blue, Dye content 60 %, ≥80% (HPLC)
Sigma-Aldrich
Trypan Blue solution, 0.4%, for microscopy
Sigma-Aldrich
Trypan Blue solution, 0.4%, liquid, sterile-filtered, suitable for cell culture